Microsatellite Instability-High/Mismatch Repair-Deficient Disease
‘Practice-changing data’ support first-line immunotherapy combination in colorectal cancer
CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.
FDA approves Keytruda for advanced endometrial carcinoma subset
The FDA approved pembrolizumab for certain women with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.
Pembrolizumab shows durable activity in subset of women with endometrial cancer
Pembrolizumab showed strong and lasting antitumor activity in women with previously treated, advanced microsatellite instability-high or mismatch repair-deficient endometrial cancer, according to a study in Journal of Clinical Oncology.
Neoadjuvant nivolumab plus ipilimumab active in subset of patients with gastric cancers
Neoadjuvant treatment with nivolumab and ipilimumab led to a high rate of pathologic complete response among patients with resectable microsatellite instability-high/mismatch repair deficient gastric cancers, study results showed.